K2

K2 tapped to host Space Force satellite laser links tests

K2 Space Secures U.S. Space Force Optical Link Work

Space Force awards K2 Space $22.9 million for laser communications demonstration

FDA Approves Abbott HIV Combo Next Assay Under 510(k) BK261345 On June 29, 2026

https://www.fda.gov/vaccines-blood-biologics/substantially-equivalent-510k-device-information/bk261345-hiv-combo-next-assay

Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside

Eli Lilly (NYSE:LLY) reported Phase 1 data for AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis patients. The AJX-101 study focused on individuals whose disease continued after prior type I JAK2 inhibitor treatment. Early results showed encouraging safety findings and clinical activity in this difficult to treat group. Eli Lilly is widely associated with its obesity drug portfolio, but the AJ1-11095 update highlights a broader pipeline that includes hematology and...

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. This first-in-class type II JAK2 inhibitor was designed to selectively bind the type II conformation of the JAK2 kinase in order to potentially provide greater efficacy than existing ther

K2 Space, Rocket Lab win key supplier roles in Space Force satcom program